TMCnet News
The China Precision Medicine Cloud: A world-leading platform to benefit patients and healthHuawei, WuXi AppTec and WuXi NextCODE launch the most powerful, proven and quality-certified national-scale cloud infrastructure for using the genome to improve medicine and health - Will benefit patients by accelerating capabilities in discovery, clinical medicine and wellness - The world's leading genomics platform hosted on China's secure and reliable cloud network - A unified infrastructure to serve the China Precision Medicine Initiative, genome discovery of unrivalled scale, as well as clinical diagnostics and drug development SHENZHEN and SHANGHAI, China, CAMBRIDGE, Massachusetts, and REYKJAVIK, Iceland, May 24, 2016 /PRNewswire/ -- Huawei, a leading global information and communications technology provider, and WuXi AppTec, the global open-access R&D platform, today launched the China Precision Medicine Cloud at a ceremony in Shanghai. This platform brings together three unique elements: Huawei's industry-leading capabilities and national network for cloud computing; the globally recognized medical innovation expertise of WuXi AppTec; and the unrivalled competence of its subsidiary WuXi NextCODE in organizing, mining and sharing genomics big data. Logo - http://photos.prnewswire.com/prnh/20150915/266982LOGO The technology in this platform underpins data infrastructure across China and the largest and most advanced precision medicine projects around the world – from national genome projects to gene discovery, clinical diagnostics, targeted pharmaceutical development and scientific wellness. It will link scientific excellence and data from across China through a secure nationwide network and governmental, medical, academic and industry collaborations. A unified cloud that enables both clinical and research genomics in real time, online is the foundation for delivering precision medicine efficiently at national scale. WuXi AppTec and Huawei will follow the guidance of the China Food and Drug Administration (CFDA) and work closely with partner life-science cloud providers to develop the data standards and exchange framework required to deliver the China PMI. WuXi AppTec and WuXi NextCODE solutions already meet US CAP and CLIA standards and include HIPAA-compliant DNAnexus technology delivering the precisionFDA in the United States, so that in implementing guidelines developed by the CFDA the China Precision Medicine Cloud will be well positioned for global compliance and collaboration. "It is an honor to have the opportunity to do our part in enabling doctors, scientists, companies and policymakers to develop and implement the most advanced precision medicine across China," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "The China Precision Medicine Cloud aims to harness unique strengths to accelerate innovation. This collaboration is a direct extension of the WuXi commitment to services with high clinical impact, leveraging big data to create the one kind of value that matters: benefit for people and patients." "We are focused on unlocking the full potential of precision medicine in China," said Hannes Smarason, COO of WuXi NextCODE. "This is a big data challenge, and what we are creating here is the fusion of the largest scale genomics platform and the leading China cloud network. It is a win-win for China Precision Medicine and its impact here and around the world." About Huawei About WuXi AppTec About WuXi NextCODE
|